학술논문

The Role of Free and Cued Selective Reminding Test in Predicting [18F]Florbetaben PET Results in Mild Cognitive Impairment and Mild Dementia.
Document Type
Journal Article
Source
Journal of Alzheimer's Disease. 2020, Vol. 73 Issue 4, p1647-1659. 13p.
Subject
*MILD cognitive impairment
*DEMENTIA
*ALZHEIMER'S disease
*NEUROPSYCHOLOGICAL tests
*COGNITION disorders
*MEMORY
*DISEASE progression
*RESEARCH
*PREDICTIVE tests
*RESEARCH methodology
*MEDICAL cooperation
*EVALUATION research
*AMINES
*STILBENE
*COMPARATIVE studies
*RADIOPHARMACEUTICALS
*BODY burden
*PROMPTS (Psychology)
*LONGITUDINAL method
*CEREBRAL amyloid angiopathy
RESEARCH evaluation
Language
ISSN
1387-2877
Abstract
Background: Free and Cued Selective Reminding Test (FCSRT) is a reliable cognitive marker for Alzheimer's disease (AD), and the identification of neuropsychological tests sensitive to the early signs of AD pathology is crucial both in research and clinical practice.Objective: The study aimed to ascertain the ability of FCSRT in predicting the amyloid load as determined from amyloid PET imaging (Amy-PET) in patients with cognitive disorders.Methods: For our purpose, 79 patients (71 MCI, 8 mild dementia) underwent a complete workup for dementia, including the FCSRT assessment and a [18F]florbetaben PET scan. FCSRT subitem scores were used as predictors in different binomial regression models.Results: Immediate free recall and delayed free recall were the best predictors overall in the whole sample; whereas in patients <76 years, all models further improved with immediate total recall (ITR) and Index of Sensitivity of Cueing (ISC) resulting the most accurate in anticipating Amy-PET results, with a likelihood of being Amy-PET positive greater than 85% for ITR and ISC scores of less than 25 and 0.5, respectively.Conclusion: FCSRT proved itself to be a valid tool in dementia diagnosis, also being able to correlate with amyloid pathology. The possibility to predict Amy-PET results through a simple and reliable neuropsychological test might be helpful for clinicians in the dementia field, adding value to a paper and pencil tool compared to most costly biomarkers. [ABSTRACT FROM AUTHOR]